Recent advances in the efficacy and tolerability of hepatitis C treatments and the introduction
of a universal access scheme for the new Direct Acting Antiviral (DAA) therapies in March …

In 2011, the protease inhibitors boceprevir and telaprevir were approved in the United
States and European Union for the treatment of hepatitis C infection. While remarkably …

Hepatitis C virus (HCV) is a global health concern associated with significant morbidity and
mortality. Before the approval of second-generation direct-acting antiviral agents (DAAs) …

Therapeutic options for treatment of chronic hepatitis C have improved substantially since
the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN …

An estimated 71 million people are infected with hepatitis C virus (HCV) globally, resulting in
about 400 000 deaths each year. 1 The availability of direct-acting antivirals (DAAs) offers …

Background and Aims The introduction of direct-acting antivirals for hepatitis C virus (HCV)
in Egypt led to massive treatment uptake, with Egypt's national HCV treatment program …

The availability of safe, efficacious, oral direct-acting antivirals (DAAs) have ushered in a
new era of hepatitis C treatment with potential to eliminate hepatitis C as a public health …

Universal Access through Lump-Sum Remuneration Australia's agreement to spend about 1
billion Australian dollars (US $766 million) over 5 years in exchange for an unlimited volume …

This commentary seeks to examine the role, value and importance of peer-based
programmatic approaches for ensuring the effective roll-out of the new hepatitis C (HCV) …

Background Voluntary licences are increasingly being used to expand access to patented
essential medicines in low-income and middle-income countries (LMICs). Since 2014, non …